Genentech Profits Off Wasteful Cancer Drug Vials, Suit Says

Law360 (February 27, 2019, 6:48 PM EST) -- Genentech Inc. knowingly packages excessive amounts of its pricey cancer pharmaceuticals in vials that can be used only once, meaning massive amounts of the drugs get thrown out “at great cost” to patients and health insurers, a proposed class action claims.

Genentech packages some of its most costly medications to maximize waste and maximize profits, former cancer patient Andrew Williamson of Missouri, who was treated with the drug Rituxan, said in the suit filed in California state court in San Mateo County. 

Because of the short shelf life of many of the drugs, saving the excess amounts in the vials is...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!